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Enthusiasm and a broad 
research program 
characterize growing 
Dermatology Department 
I n just three years the Department of Derma-
tology has grown f r o m one to 11 members 
and its research programs and cl inical act ivi-
ties have been expanded to make i t one of 
the top dermatology groups i n the nat ion. 
The force behind this growth is Dermatology 
chief Barhara A . Gilchrest, M . D . , w h o joined 
the Department i n 1985 f r o m Tufts Univer-
sity and the N e w England Medical Center 
(where she s t i l l heads a laboratory at the 
USDA H u m a n N u t r i t i o n Research Center on 
Aging). Her energy and innovat ion have 
made the Department a great place to be, ac-
cording to one member w h o feels "very 
lucky to he a part of i t . " 
A sampling of the types of research and 
c l inical activities under way i n the Depart-
ment includes: 
• Exploration of new laser applications i n 
dermatology. 
• Treatment of d i f f i cu l t sk in cancers hy a 
new microscopically controlled surgical tech-
nique k n o w n as Mohs surgery. 
• The estahlishment of a Cl in ica l Test 
Center for studies of new dermatologic treat-
ments, inc luding a t r i a l of ret in A for photo-
aged skin. 
• Formation of t w o innovative training 
programs: A unique jo int t ra ining program i n 
dermatology w i t h Tufts Univers i ty and the 
N e w England Medical Center and a new 
year-long certificate program i n dermatology 
for foreign health-care professionals, sched-
uled to hegin this summer. 
Crucial to the success of the Department, 
says Dr. Gilchrest, are three factors: the 
quali ty of its members, the strong interactive 
l inks between laboratory research and c l i n i -
cal practice, and the mul t id isc ip l inary char-
acter of projects under way. 
This issue of Evans Medicine highlights 
three members of the Department of Derma-
tology whose w o r k symbolizes important as-
pects of the discipline and the Evans i n gen-
eral: hasic research, education and patient 
care. • 
Monica Peacocke, M . D . , discusses her research on 
melanocytes and nerve growth factor. 
Laboratory group at 
forefront of human 
melanocyte biology 
As principal investigator of a program project 
grant on the cellular basis of aging, one of 
Dr. Gilchrest's pr incipal interests has been 
the biology of the h u m a n melanocyte, an 
area to w h i c h she has made some pioneering 
contributions. A l t h o u g h melanocytes are a 
m i n o r i t y cell type i n the epidermis after ker-
atinocytes and fibroblasts, they nevertheless 
play a key role i n photoprotection, photoag-
ing and photocarcinogenesis. I t is i n this last 
capacity that molecular biologist Monica 
Peacocke, M . D . , recruited to pursue research 
i n this area, finds t h e m so interesting. 
Dr. Peacocke, w h o joined the Department 
last year, heads the laboratory group on cuta-
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The Department 
capitalizes on 
members' innovation 
and collaborative 
projects with other 
Evans groups. 
The 
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neous gerontology. She is posing questions— 
many for the first t ime—ahout the g r o w t h 
and dif ferent iat ion of normal melanocytes 
and the possihle mechanisms involved i n 
malignant transformation. 
"The most interesting t h i n g ahout melano-
cytes for us is not their role i n tanning, hut 
the fact that they can hecome mal ignant , " 
says Dr. Peacocke, "and melanoma is a can-
cer that is galloping i n terms of incidence. 
We are prohably the first group to investigate 
aspects of melanocyte gene expression—ex-
amin ing w h i c h genes are involved i n normal 
g r o w t h and w h i c h may he involved i n trans-
f o r m a t i o n . " 
Thanks to hreakthrough contributions by 
Dr. Gilchrest over the past several years, the 
ab i l i ty to culture melanocytes has been 
vastly improved. Using these techniques. Dr. 
Peacocke and her colleagues are look ing 
closely at the role of nerve g r o w t h factor i n 
melanocyte biology and at the cell-cell inter-
actions between keratinocytes and melano-
cytes. According to Dr. Gilchrest, the group 
was the first to demonstrate i n culture that 
keratinocytes produce a series of substances 
that influence melanocyte morphology, pig-
ment product ion and g r o w t h rate. Melano-
cytes are attracted by w h a t keratinocytes 
make and these factors are cr i t ical to melan-
ocyte survival . Exactly what these mediators 
are and h o w they w o r k on melanocytes are 
the subjects of further studies i n Dr. Pea-
cocke's lab. 
Dr. Peacocke's current studies began seren-
dipitously, she says. When, w o r k i n g w i t h Dr. 
M i n a Yaar at Tufts Univers i ty , she noticed 
that melanocytes treated w i t h the t u m o r 
promot ing phorbol ester, TPA, differentiated 
to look l i k e nerve cells. (As neural crest-de-
r ived cells, melanocytes migrate early i n em-
bryonic development to the s k i n where, i n 
contact w i t h keratinocytes, they assume a 
polygonal, somewhat dendrit ic character.) 
This nerve cel l - l ike morphology suggested 
to Dr. Peacocke that receptors for nerve 
g r o w t h factor (NGF) could be found on me-
lanocytes. Gollaborating w i t h a colleague at 
Cornel l Univers i ty w h o had cloned the hu-
m a n N G F receptor, Dr. Peacocke found that 
normal melanocytes were negative for N G F 
receptor. However, cells that had been ex-
posed to the t u m o r promoter made the re-
ceptor protein. Further experiments revealed 
both the presence of prote in of the correct 
molecular weight for the N G F receptor and 
the expression of the gene for the receptor i n 
TPA-st imulated cells. 
" I f y o u give nerve g r o w t h factor to an u n -
s t imulated melanocyte, no th ing happens; 
N G F cannot interact w i t h the cell because 
there is no receptor. What we are discovering 
now is that we can induce the receptor i n a 
variety of ways , " says Dr. Peacocke. By re-
m o v i n g for a period of t i m e the serum or 
basic fibroblast g r o w t h factor—the major me-
lanocyte mitogen—needed to grow melano-
cytes i n culture, and then g iv ing the melano-
cytes NGF, she found that the cells grew 
better. " N o t as w e l l as if they had serum or 
basic fibroblast g r o w t h factor, hut clearly 
there is an effect of N G F on melanocytes at 
certain points i n their l i fe cycle." Ul t ravio le t 
i rradiat ion, a s t imulus for tanning of normal 
skin, also stimulates N G F receptor produc-
t i o n i n cultured melanocytes. 
Nerve g r o w t h factor receptors have been 
found on many h u m a n melanoma cell lines, 
but i t is not clear whether N G F is related to 
the mal ignant transformation or is just a 
marker of cellular matur i ty . To explore this 
question. Dr. Peacocke is beginning a series 
of experiments that involve inserting an am-
pl i f ied version of the gene for nerve growth 
factor receptor i n t o normal melanocytes and 
observing the changes. After three weeks of 
growth, Dr. Peacocke hopes to notice 
changes i n morphology to the nerve cell type 
and unusual g r o w t h patterns, part icularly 
c lumping, w h i c h is generally the first sign of 
malignancy. As a final step, the abnormal 
cells w i l l be injected i n t o nude mice to see if 
tumors develop. 
I n collaboration w i t h Dr. Yaar, Dr. Pea-
cocke has shown that keratinocytes produce 
N G F as w e l l , and she is pursuing investiga-
tions to elucidate the complex relationships 
between keratinocytes and melanocytes. For 
instance, i f sk in is exposed to sunlight i n 
amounts necessary to produce a tan, do the 
keratinocytes make more NGF, and is i n -
creased N G F product ion involved i n melano-
cyte transformation? She also is interested i n 
the proteins that enable melanocytes to 
m a i n t a i n their long dendritic processes and 
is look ing especially at fihronectin and l a m i -
n i n , w h i c h are t w o large extracellular matr ix 
proteins synthesized hy neighboring keratin-
ocytes. The hypothesis is that as melano-
cytes encounter these proteins, the melano-
cytes differentiate and a sequence of genes 
involved i n the dif ferentiat ion program are 
induced. 
A l t h o u g h Dr. Peacocke is looking at the 
specific genetic steps involved i n the melan-
ocyte dif ferentiat ion f r o m normal polygonal 
to dendritic nerve-cell form, part icularly the 
events that occur i n the first 30 minutes to 
one hour after exposure to TPA, she also is 
looking at the sequence of gene act ivation i n 
normal melanocytes. 
" O n l y through a meticulous exploration of 
normal g r o w t h and differentiat ion can we 
come to understand the abnormal growth i n -
volved i n malignancy," she says. • 
E V A N S 
M E D I C I N E 
TPA-stimulated melano-
cytes stain positive for 
N G F receptors with im-
muno fluorescent mono-
clonal antibody. 
Dermatologist studies 
melanoma prevention, 
blood cancer treatment 
Research i n the Department of Dermatology 
is not restricted to the laboratory bench, and 
the w o r k of H o w a r d Koh, M . D . , is a case i n 
point . Dr. Koh is board certified i n internal 
medicine, hematology, oncology and derma-
tology and presently has appointments i n the 
School of Puhlic Heal th and the Departments 
of Medic ine and Dermatology. He is p u t t i n g 
his broad t ra in ing to good use i n the study of 
skin cancer, part icularly melanoma, and its 
prevention. 
" M y overall interest is i n the public-health 
aspects of cancer and the early detection and 
prevention of cancer. Melanoma is an excel-
lent t u m o r model to study because even 
though the rate of incidence is increasing 
faster than any other cancer, except for lung 
cancer i n w o m e n , and the number of deaths 
f r o m melanoma is increasing, the potential 
for early detection and prevention is great." 
Dr. Koh and colleagues i n the School of 
Puhlic Hea l th are researching how to i m -
prove the early detection and prevention of 
melanoma and whether screening helps to 
control the number of deaths. Dr. Koh is a 
member of a national committee of the 
Amer ican Academy of Dermatology (AAD) 
that is looking in to sk in cancer prevention. 
The A A D has organized yearly nat ionwide 
screening clinics as part of this effort. 
According to Dr. Koh, more than 100,000 
people, inc luding approximately 2,500 i n 
Massachusetts, have been screened i n the 
past three years during l i m i t e d screening 
campaigns. Such clinics w i l l be held again 
this year at a number of sites, inc luding at 
B U M C , where dermatologists i n the Evans 
Medical Group have donated their t i m e to 
conduct examinations for s k i n cancer. (Last 
year, 116 people were screened during t w o 
days at the Evans Medical Group; 25 percent 
were thought to have c l in ica l ly suspicious 
lesions and were referred to their o w n physi-
cians for fol low-up.) Dr. Koh is active i n co-
ordinat ing the Massachusetts melanoma 
screening efforts i n order to obtain hard data 
on whether the screening programs w o r k . 
This effort includes t racking what happens 
to individuals f o l l o w i n g the screening— 
whether cancer was diagnosed and what the 
pathology and outcomes were. 
Dr. Koh uses the t e r m "applied epidemiol-
ogy" to describe his prevention efforts, 
w h i c h involve using al l available data on 
melanoma, inc luding w h o is at r isk for i t and 
w h a t the r isk factors are, i n order to prevent 
the disease or at least keep i t f r o m reaching 
an incurable stage. 
I n addi t ion to screening, educational ef-
forts have been aimed at teaching i n d i v i d u -
als, pr imary care physicians and nurse practi-
tioners to rout ine ly check for signs of 
melanoma. Dr. K o h has contributed to these 
efforts as a member of the board of directors 
of the Massachusetts Ghapter of the A m e r i -
can Cancer Society. Similar campaigns have 
proved effective for breast cancer detection 
and prevention and, according to Dr. Koh, 
should w o r k as w e l l for melanoma. 
I n addit ion to his public health w o r k . Dr. 
Koh is the director of photopheresis at the 
Univers i ty Hospital . Photopheresis is a new 
technique used to treat people w i t h a severe 
f o r m of the s k i n cancer cutaneous T cell 
lymphoma. Cutaneous T cell lymphoma is a 
relatively u n c o m m o n t u m o r compared to 
melanoma, but i t can appear i n a wide range 
of forms. The most advanced phase, called 
Sezary's syndrome, occurs w h e n malignant T 
cells i n the sk in move i n t o the bloodstream 
and the patient develops leukemia as w e l l . 
(Dr. Koh recently was awarded a Whitaker 
Heal th Sciences Fund grant i n collaboration 
w i t h Dr. Herman Eisen of the Massachusetts 
Inst i tute of Technology to explore the basis 
of photopheresis' beneficial effect.) 
The Univers i ty Hospita l is one of 10 cen-
ters i n the country offering photopheresis. 
The technique involves removing a patient's 
blood by a dialysis machine, separating out 
the malignant T cells and shining long wave 
ul traviolet l ight on these cells, w h i c h acti-
vates the drug, psoralen, that the patients 
have taken prior to the procedure. The pho-
toactivated drug affects the malignant cells 
and the blood is then returned to the patient. 
Exactly how the process works is u n k n o w n , 
but i t is thought that by damaging cells w i t h 
l ight , photopheresis allows for more rapid de-
struct ion of the malignant cells, conceivably 
through an immunolog ic mechanism. 
The treatment helped approximately 75 
percent of the patients i n a first series stud-
ied at Yale Univers i ty . " I n theory this might 
w o r k w i t h other, more c o m m o n diseases, 
such as chronic lymphocyt i c leukemia and 
chronic rheumatoid a r t h r i t i s , " says Dr. Koh, 
w h o plans to start protocols this summer 
w i t h collaborators i n the Evans Sections of 
Hematology and A r t h r i t i s . • 
Howard Koh, M . D . , is pursuing research in mela-
noma prevention and photopheresis, a new therapy 
for patients with Sezary's syndrome. 
Screening has the potential 
to catch melanoma before 
it becomes deadly. 
'Although the number 
of deaths from 
melanoma is rising, 
the potential for early 
detection and 
prevention is great/ 
Noteworthy 
International ly k n o w n expert on hyperten-
sion Aram Chobanian, M.D., chief of the Ev-
ans Hypertension Section and professor of 
medicine and pharmacology, became the 
16th dean of Boston Univers i ty School of 
Medicine, effective M a y 1. 
A m o n g other recent achievements. Dr. 
Chobanian presented the 1988 Report of the 
Joint N a t i o n a l Commit tee (JNC IV) on the 
Detection, Evaluation and Treatment of H y -
pertension at an A p r i l press conference i n 
Bethesda, M d . , sponsored by N H E B l . Dr. 
Chobanian is chairman of the JNC IV com-
mittee , and the report was scheduled to ap-
pear as a special article i n the M a y 1988 is-
sue of the Archives of Internal Medicine. 
Dr. Chobanian also received the 1987 East-
m a n Kodak A w a r d of the Nat ional Academy 
of C l in ica l Biochemistry for his research on 
the relationships between hypertension and 
atherosclerosis. 
David Beller, Ph.D., w h o heads the Evans 
Research I m m u n o l o g y U n i t , has heen invi ted 
to speak at the Second International Work-
shop on Macrophage Biology and A c t i v a t i o n 
this July. 
Richard D . Diamond, M.D., chief of the In-
fectious Disease Section, recently was 
elected a member of the American Associa-
t i o n of Physicians. Richard A. Cohen, M.D., 
of the Peripheral Vascular Section, and 
Thomas Rothstein, M.D. , Ph.D., of the He-
matology Section, were elected to member-
ship i n the American Society for Cl in ica l In -
vestigation. Both organizations encompass al l 
specialties and election to t h e m recognizes 
outstanding research accomplishments and 
nat ional and internat ional reputation. 
Matt Fenton, Ph.D., recently joined the Ev-
ans as a research professor of medicine i n the 
I m m u n o l o g y Section. His interest is i n mo-
lecular mechanisms of regulating l E - l ex-
pression. 
William Kannel, M.D. , chief of the Section of 
Preventive Medicine and Epidemiology, re-
ceived a Dist inguished Service A w a r d this 
spring f r o m the American College of Cardiol-
ogy at the College's annual meeting i n A t -
lanta. 
Evans Director Norman G . Levinsky, M.D., 
Wade Professor of Medicine and chairman of 
the D i v i s i o n of Medicine at BUSM, recently 
was elected a Master of the American Col-
lege of Physicians. He also is serving as pres-
ident of the Association of Professors of 
Medic ine for the 1988-89 term. 
Ronald McCaffrey, M.D. , chief of the Section 
of Medical Oncology, served as chairman of 
the Leukemia Society of America's annual 
meeting i n N e w Orleans i n March. Paul Hes-
keth, M.D. , an assistant professor of medi-
cine i n the same Section, presented a lecture 
on the increasing frequency of adenocarci-
noma of the esophagus i n Massachusetts at 
the recent annual meeting of the Amer ican 
Society of Cl in ica l Oncology, also i n N e w 
Orleans. 
Mark Moskowitz, M.D., has heen appointed 
chief of the Evans General Internal Medicine 
Section. Dr. M o s k o w i t z previously had been 
i n charge of the Heal th Care Research U n i t 
i n that Section. 
Karen Freund, M.D., also of the General I n -
ternal Medicine Section, has heen named di -
rector of the Women's Heal th Group, effec-
t ive July 1, 1988. She replaces Linda Lesky, 
M.D. , w h o is leaving to pursue research i n 
cl inical epidemiology at Harvard Medical 
School. 
Evans member Michael Rosenbaum, M.D., 
an associate c l in ica l professor of dermatol-
ogy, has heen elected secretary-treasurer of 
the N e w England Dermatological Society. 
Neil Ruderman, M.D. , Ph.D., head of the 
Diahetes-Metabolism U n i t i n the Evans Sec-
t i o n of Endocrinology and Metabol ism, was a 
v i s i t i n g professor at Louisiana State Univer-
sity and the Univers i ty of Tennessee Schools 
of Medicine i n March . Anthony McCall , 
M.D., an assistant professor of medicine and 
physiology i n the same Section, is an invited 
speaker for the Symposium on Hypoglycemi; 
organized by the International Diabetes Fed-
eration, to be held i n Sydney, Australia, i n 
November. 
David Salant, M.D. , a professor of medicine 
and pharmacology, was named head of the 
Renal U n i t and the Renal Section of the De-
partment of Medicine i n 1987. 
R. Knight Steel, M.D. , chief of the Evans 
Geriatric Section, is serving as chairman of 
the Gert i fying Examinat ion Commit tee i n 
Geriatric Medic ine of the American Board ol 
Internal Medic ine and the American Board o 
Family Practice. I n A p r i l , Dr. Steel was 
among a panel of experts discussing issues 
related to aging and health care during an i n 
teractive video teleconference, moderated by 
Ted Koppel of ABG. The program, enti t led 
" A g i n g i n America : D i g n i t y or Despair," was 
broadcast l ive to special conference centers 
across the country. 
Joseph Stokes, M.D. , a member of the Sec-
t i o n of Preventive Medic ine and Epidemiol-
ogy, received medals f r o m the Swedish Soci-
ety of Medicine and the Society for 
Prospective Medicine i n recognition of his 
research i n preventive medicine and epide-
miology. I n addit ion. Dr. Stokes, w h o directs 
the Framingham Offspring Study, presented a 
lecture i n A p r i l on the Nat iona l Cholesterol 
Education Program at Prevention '88. 
Aram V, Chobanian, M . D . 
Skin graft technique holds 
promise for patients 
with chronic wounds 
Since jo in ing the Department a year and a 
half ago, geriatric dermatology fe l low Tania 
Phill ips, M . D . , has been heading a cl inical 
research program using cultured skin allo-
grafts to treat intractable sk in ulcers. I t has 
been estimated that 1.5 m i l l i o n Americans 
suffer f r o m chronic, nonhealing wounds. 
People w i t h diabetes, older people w i t h poor 
c irculat ion and cancer chemotherapy pa-
tients may be especially prone to delayed or 
failed healing. Dr. Phi l l ips ' approach involves 
cu l tur ing small pieces of discarded foreskins 
f r o m newborns in to large sheets of cells that 
can be placed directly onto wounds. 
Before coming to the U n i t e d States, ex-
plains Dr. Phill ips, she was a cl inical derma-
tologist at the London Hospital i n London, 
England, where she treated many patients 
w i t h persistent leg ulcers. "One of the ways 
to treat these problems is w i t h a spl i t - thick-
ness skin graft, using skin f rom the thigh to 
cover the w o u n d . The problem w i t h this ap-
proach, especially w i t h older patients, is that 
you leave a w o u n d i n the thigh, w h i c h itself 
can he painful and take a long t ime to heal ." 
The split-thickness approach also l i m i t s the 
size of the w o u n d that can be treated. 
When she arrived i n Boston, Dr. Phill ips 
spent t i m e i n the laboratory of Dr. Howard 
Green of Harvard University, where she 
learned how to grow the cells i n culture. 
" D r . Green developed the method of taking a 
t i n y piece of skin f r o m a person, growing i t 
to many times its original size and then us-
ing this bigger piece to treat the wound. In 
early trials this worked pretty wel l , but the 
problem again was that w i t h older patients 
the sk in cells are older and just don't grow as 
w e l l , " Dr. Phil l ips explains, "so people won-
dered what else could he t r i e d . " 
D r a w i n g on Dr. Gilchrest's findings of age-
related losses i n the proliferative potential of 
sk in cells. Dr. Phil l ips decided that a good 
possibil i ty might be to use newborn fore-
skins because young cells grow so m u c h bet-
ter i n culture than older skip and because 
newborn cells generate large amounts of 
growth factors. 
She has treated about 40 patients so far at 
the Univers i ty Hospital using cultured neo-
natal cells, and has been getting excellent re-
sults—over 70 percent of patients' wounds 
have healed completely and most of the rest 
have shown improvement . First, the ulcer is 
cleaned w i t h conventional topical treat-
ments, then the layer of cultured cells at-
tached to a gauze backing is applied and ban-
daged over. If the patient can rest at home 
and stay off his or her feet for the first week, 
there is no need for hospitalization; if not. 
Dr. Phil l ips does her best to have the patient 
admitted. After the first week, the gauze is 
removed and the patients can continue to 
dress the w o u n d themselves u n t i l healing is 
complete. 
With patient looking on, Tania Phillips, M.D. , describes cultured 
allograft procedures. 
"The interesting t h i n g , " says Dr. Phill ips, 
" is the way the allograft works, because this 
is foreign tissue." A t first, she says, the re-
sults were so dramatic that she thought the 
graft must be taking. Further studies have i n -
dicated, however, that the allografts do not 
remain i n place permanently, but are s lowly 
rejected as the host tissue repairs itself. Biop-
sies performed after three or four weeks do 
not reveal any foreign tissue at al l . 
"We t h i n k the combinat ion of a biological 
dressing, w h i c h keeps the w o u n d moist and 
protects i t f r o m the air, and the r ich m i x of 
growth factors secreted by the neonatal cells 
st imulate the patient's o w n skin cells to be 
more active and fill i n the wound, w h i c h 
they couldn't do before," says Dr. Phil l ips. 
I t also is possible that the loss of the donor 
skin's Langerhans cells during the culture 
process makes the graft m u c h less antigenic 
than a conventional graft of noncultured tis-
sue. 
Another positive aspect of the allograft 
treatment, according to Dr. Phill ips, is the 
almost immediate relief f r o m pain that many 
patients experience—pain that for many has 
heen constant during the months or years 
during w h i c h the ulcer has failed to heal. 
U n t i l now. Dr. Phil l ips has been doing an 
uncontrol led t r ia l of this treatment, fo l low-
ing the w o u n d healing process i n each pa-
tient, tracking the t ime the process takes and 
the pattern of healing. A comparison of u l -
cers that heal completely and those that 
don't showed a pattern of dramatic improve-
ment i n both during the first t w o weeks, fol -
lowed by a tapering off i n some cases. " I f a 
w o u n d is going to heal at all , you can usu-
ally te l l i n the first four weeks," she says. 
Beginning this summer, she w i l l head a 
large randomized study i n collaboration w i t h 
groups at the Boston Veterans Administra-
t i o n Medical Center and Brown University 's 
Roger W i l l i a m s Hospital i n w h i c h some pa-
tients w i l l receive cultured allografts w h i l e 
others w i l l only receive the gauze dressing. 
A t the moment , she is seeking patients to 
include i n this next phase of research. • 
So far, more tlian 70 
percent of her 
patients treated with 
cultured allografts 
experienced complete 
wound healing. 
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Evans/Transition 
Kenneth Steinherg, M . D . , has been named 
chief resident for the 1988-1989 academic 
year. Born i n Brooklyn, N.Y., and raised i n 
Stamford, Conn., Dr. Steinberg received his 
medical degree f r o m N e w York Medical Col-
lege. He is just finishing his t h i r d year as a 
resident i n internal medicine and w i l l start 
his chief residency July 1 . 
Fol lowing his year as chief medical resi-
dent. Dr. Steinberg expects to begin a pulmo-
nary medicine fel lowship, although he is not 
yet sure where. His research interests focus 
on vascular mediators and their role i n p u l -
monary vascular disease. Dr. Steinberg also is 
interested i n the development and treatment 
of in ters t i t ia l lung disease. 
I n addit ion to patient-care duties. Dr. 
Steinberg helps teach the advanced cardio-
pulmonary l i fe support course of the A m e r i -
can Heart Association to nurses, interns and 
other residents at the Medical Center, and he 
instructs second-year medical students i n 
physical diagnosis. 
"I def ini te ly w o u l d l ike to get a posit ion i n 
academic medicine. 1 enjoy teaching, thr ive 
on patient care and have research interests as 
w e l l , so 1 w o u l d prefer a s i tuat ion that com-
bines al l three." 
A tota l of 20 interns have joined the Evans 
this year. They are: 
Christopher dlFilippi, M.D., Univers i ty of 
Rochester School of Medicine 
Judy Fine, M.D., Tufts Univers i ty School of 
Medicine 
John Freedman, M.D., Univers i ty of Pennsyl-
vania School of Medicine 
Howard Goldberg, M.D., Albert Einstein Col-
lege of Medic ine 
Robert Goldberg, M.D. , Univers i ty of Cali-
fornia-San Diego School of Medicine 
James Hoffman, M.D., Boston Univers i ty 
School of Medicine 
Michael Hollett, M.D., D u k e Univers i ty 
School of Medicine 
Abram Kirschenbaum, M.D., N e w York U n i -
versity School of Medicine 
Glenn Levine, M.D. , Columbia College of 
Physicians and Surgeons 
Wendy Livingston, M.D. , Columbia College 
of Physicians and Surgeons 
Mary Manning, M.D., George Washington 
Univers i ty School of Medicine 
Andrew Nichols, M.D., Boston Univers i ty 
School of Medicine 
Joseph Polito, M.D., Medical College of Vir-
ginia 
Bruce Randazzo, M.D. , State Univers i ty of 
N e w York at Stony Brook School of Medi-
cine 
Lisa Renfro, M.D., Univers i ty of Connecticut 
School of Medicine 
Monique Roth, M.D. , Univers i ty of Connect-
icut School of Medicine 
Jeffrey Silver, M.D. , Boston Univers i ty 
School of Medicine 
Lynn Sydor, M.D., Univers i ty of Pittsburgh 
School of Medicine 
Robert Tarpy, M.D., Univers i ty of Massachu-
setts Medical School 
Arthur Zerbey, M.D., Univers i ty of Minne-
sota School of Medicine 
Thir teen Evans memhers complete their resi-
dencies i n July. The graduates and their fu -
ture pursuits are: 
Manuel Anton, M.D., (cardiology) 
Andrew Chodos, M.D., Boston Univers i ty 
Medical Center (cardiology) 
Peter Francis, M.D., Nat iona l Cancer Inst i -
tute (oncology) 
Russel Gerry, M.D., private practice i n Con-
cord, Mass. 
Eric Manning, M.D. , Boston Univers i ty Med-
ical Center (research fel lowship i n bio-
chemistry) 
Craig Morita, M.D., Brigham &. Women's 
Hospital , Boston (rheumatology) 
Joanne Murabito, M.D., Framingham Heart 
Study 
Margaret O'Donoghue, M.D., Harvard U n i -
versity (neurology) 
Alan Steele, M.D. , Beth Israel Hospital , Bos-
ton (renal medicine) 
Kenneth Steinberg, M.D., The Univers i ty 
Hospital , Boston (chief medical resident) 
Richard Taikowski, M.D., M t . Sinai Hospi-
tal , N e w York (cardiology) 
Robert Weiss, M.D., (gastroenterology) 
Anthony White, M.D., (infectious disease) • 
New chief medical resident 
Kenneth Steinberg, M . D . 
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